Alimera

On behalf of the CALM registry study investigators and supporting clinical sites, Dr. Abbey presented real-world outcomes of the fluocinolone acetonide intravitreal implant for non-infectious uveitis of the posterior segment at the recent annual meeting of the American Society of Retina Specialists (ASRS). Learn more in our latest blog: https://lnkd.in/epgFqUdM

In the phase 4 CALM study, the Yutiq implant showed: 👉Reduction in the rate of #uveitis recurrence. 👉Reduction in inflammatory flares. 👉Stabilization of #vision. And more! 🔗 #ocularSurgeryNews #ASRS2024 ASRS – American Society of Retina Specialists https://lnkd.in/gc7Je5_Q

It’s our shared vision that propels us forward. 💪🌟 From long-lasting retinal treatments to positive outcomes in collaboration with providers, we believe in the strength of collective efforts. One of us is never as valuable as ALL of us. Learn how We See More, Together™ here: https://bit.ly/3Tgrunl

Are you passionate about ophthalmology and looking for a new and exciting opportunity? We're expanding our team in Germany and we want you to be a part of our innovative and dynamic organization. Check out some of the exciting positions we are hiring for: 🌟 MSL - North East Germany 🌟 Clinical Account Specialist - Frankfurt, Aschaffenburg, Wuerzburg 🌟Clinical Account Specialist - Augsburg, Ingolstadt, Nuremberg For more details & to apply click here! 👇 https://lnkd.in/eGzNQFke

At the heart of our company is a shared passion for protecting the retina and preserving vision. Through our collective knowledge, durable treatments, and collaborative efforts with providers, patients, and partners, we are committed to making a positive difference. Learn more about our journey to protect and enhance vision on our website here: https://bit.ly/3Tgrunl

Stay up-to-date on some exciting things happening at Alimera. Click to read more: https://bit.ly/3Rw4Plj

We are proud of the impact we are making in the world of vision. Check out our news: https://bit.ly/4b7mZ3S

Join us in celebrating these June work anniversaries for another amazing year of helping patients see clearly! 🎊 Each year brings new accomplishments, new challenges, and new successes, so thank you for all you do as part of our Alimera team. 👏 https://bit.ly/3Tgrunl

Alimera is excited to engage with other retinal thought leaders at Clinical Trials at the Summit (CTS) in Park City, Utah. Come see us as we contribute to the discourse on ongoing clinical trials and the latest data driving progress in retinal health. https://bit.ly/3Tgrunl

Completion of enrollment in the SYNCHRONICITY Study for YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is a key step in assessing its impact. This article from the @ReviewofOphthalmology delves into the study's progress and sheds light on the potential impact YUTIQ has on advancing ophthalmological treatment. Read the full article here: https://bit.ly/3P01idK